Effects of an oral GH [growth hormone] secretagogue (MK-677) [Ibutamoren] on body composition and functional ability of older adults

Trial Profile

Effects of an oral GH [growth hormone] secretagogue (MK-677) [Ibutamoren] on body composition and functional ability of older adults

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2007

At a glance

  • Drugs Ibutamoren (Primary)
  • Indications Alzheimer's disease; Fibromyalgia; Fracture; Muscular atrophy; Postmenopausal osteoporosis; Somatotropin deficiency
  • Focus Pharmacodynamics
  • Acronyms MOT089
  • Most Recent Events

    • 30 Jul 2007 The expected completion date for this trial is now 1 Jun 2004.
    • 20 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top